vs

Side-by-side financial comparison of Charles River Laboratories (CRL) and Microchip Technology (MCHP). Click either name above to swap in a different company.

Microchip Technology is the larger business by last-quarter revenue ($1.3B vs $995.8M, roughly 1.3× Charles River Laboratories). Microchip Technology runs the higher net margin — 11.0% vs -1.5%, a 12.5% gap on every dollar of revenue. On growth, Charles River Laboratories posted the faster year-over-year revenue change (1.2% vs -72.2%). Over the past eight quarters, Microchip Technology's revenue compounded faster (2.8% CAGR vs -1.5%).

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

Microchip Technology Incorporated is an American publicly traded semiconductor corporation that manufactures microcontroller, mixed-signal, analog, and Flash-IP integrated circuits.

CRL vs MCHP — Head-to-Head

Bigger by revenue
MCHP
MCHP
1.3× larger
MCHP
$1.3B
$995.8M
CRL
Growing faster (revenue YoY)
CRL
CRL
+73.4% gap
CRL
1.2%
-72.2%
MCHP
Higher net margin
MCHP
MCHP
12.5% more per $
MCHP
11.0%
-1.5%
CRL
Faster 2-yr revenue CAGR
MCHP
MCHP
Annualised
MCHP
2.8%
-1.5%
CRL

Income Statement — Q1 FY2026 vs Q4 FY2026

Metric
CRL
CRL
MCHP
MCHP
Revenue
$995.8M
$1.3B
Net Profit
$-14.8M
$144.2M
Gross Margin
61.0%
Operating Margin
12.0%
16.6%
Net Margin
-1.5%
11.0%
Revenue YoY
1.2%
-72.2%
Net Profit YoY
-157.2%
8.9%
EPS (diluted)
$-0.30
$0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRL
CRL
MCHP
MCHP
Q1 26
$995.8M
$1.3B
Q4 25
$994.2M
$1.2B
Q3 25
$1.0B
$1.1B
Q2 25
$1.0B
$1.1B
Q1 25
$984.2M
$970.5M
Q4 24
$1.0B
$1.0B
Q3 24
$1.0B
$1.2B
Q2 24
$1.0B
$1.2B
Net Profit
CRL
CRL
MCHP
MCHP
Q1 26
$-14.8M
$144.2M
Q4 25
$-276.6M
$62.7M
Q3 25
$54.4M
$41.7M
Q2 25
$52.3M
$-18.6M
Q1 25
$25.5M
$-154.6M
Q4 24
$-214.5M
$-53.6M
Q3 24
$69.7M
$78.4M
Q2 24
$94.1M
$129.3M
Gross Margin
CRL
CRL
MCHP
MCHP
Q1 26
61.0%
Q4 25
59.6%
Q3 25
55.9%
Q2 25
53.6%
Q1 25
51.6%
Q4 24
54.7%
Q3 24
34.6%
57.4%
Q2 24
34.5%
59.4%
Operating Margin
CRL
CRL
MCHP
MCHP
Q1 26
12.0%
16.6%
Q4 25
-28.5%
12.8%
Q3 25
13.3%
7.8%
Q2 25
9.7%
3.0%
Q1 25
7.6%
-10.3%
Q4 24
-16.7%
3.0%
Q3 24
11.6%
12.6%
Q2 24
14.8%
17.7%
Net Margin
CRL
CRL
MCHP
MCHP
Q1 26
-1.5%
11.0%
Q4 25
-27.8%
5.3%
Q3 25
5.4%
3.7%
Q2 25
5.1%
-1.7%
Q1 25
2.6%
-15.9%
Q4 24
-21.4%
-5.2%
Q3 24
6.9%
6.7%
Q2 24
9.2%
10.4%
EPS (diluted)
CRL
CRL
MCHP
MCHP
Q1 26
$-0.30
$0.21
Q4 25
$-5.57
$0.06
Q3 25
$1.10
$0.03
Q2 25
$1.06
$-0.09
Q1 25
$0.50
$-0.29
Q4 24
$-4.17
$-0.10
Q3 24
$1.33
$0.14
Q2 24
$1.74
$0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRL
CRL
MCHP
MCHP
Cash + ST InvestmentsLiquidity on hand
$191.8M
$240.3M
Total DebtLower is stronger
$5.5B
Stockholders' EquityBook value
$2.9B
$6.4B
Total Assets
$7.7B
$14.4B
Debt / EquityLower = less leverage
0.85×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRL
CRL
MCHP
MCHP
Q1 26
$191.8M
$240.3M
Q4 25
$213.8M
$250.7M
Q3 25
$207.1M
$236.8M
Q2 25
$182.8M
$566.5M
Q1 25
$229.4M
$771.7M
Q4 24
$194.6M
$586.0M
Q3 24
$210.2M
$286.1M
Q2 24
$179.2M
$315.1M
Total Debt
CRL
CRL
MCHP
MCHP
Q1 26
$5.5B
Q4 25
$2.1B
$5.4B
Q3 25
$2.2B
$5.4B
Q2 25
$2.3B
$5.5B
Q1 25
$2.5B
$5.6B
Q4 24
$2.2B
$6.7B
Q3 24
$2.3B
$6.4B
Q2 24
$2.4B
$6.2B
Stockholders' Equity
CRL
CRL
MCHP
MCHP
Q1 26
$2.9B
$6.4B
Q4 25
$3.2B
$6.6B
Q3 25
$3.4B
$6.7B
Q2 25
$3.4B
$6.9B
Q1 25
$3.2B
$7.1B
Q4 24
$3.5B
$6.0B
Q3 24
$3.8B
$6.3B
Q2 24
$3.7B
$6.4B
Total Assets
CRL
CRL
MCHP
MCHP
Q1 26
$7.7B
$14.4B
Q4 25
$7.1B
$14.3B
Q3 25
$7.5B
$14.5B
Q2 25
$7.6B
$15.0B
Q1 25
$7.6B
$15.4B
Q4 24
$7.5B
$15.6B
Q3 24
$8.0B
$15.6B
Q2 24
$7.9B
$15.8B
Debt / Equity
CRL
CRL
MCHP
MCHP
Q1 26
0.85×
Q4 25
0.68×
0.82×
Q3 25
0.64×
0.80×
Q2 25
0.70×
0.80×
Q1 25
0.79×
0.80×
Q4 24
0.65×
1.12×
Q3 24
0.62×
1.02×
Q2 24
0.65×
0.96×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRL
CRL
MCHP
MCHP
Operating Cash FlowLast quarter
$41.1M
Free Cash FlowOCF − Capex
$242.8M
FCF MarginFCF / Revenue
18.5%
Capex IntensityCapex / Revenue
5.6%
1.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$871.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRL
CRL
MCHP
MCHP
Q1 26
$41.1M
Q4 25
$147.5M
$341.4M
Q3 25
$213.8M
$88.1M
Q2 25
$204.6M
$275.6M
Q1 25
$171.7M
$205.9M
Q4 24
$159.4M
$271.5M
Q3 24
$251.8M
$43.6M
Q2 24
$193.5M
$377.1M
Free Cash Flow
CRL
CRL
MCHP
MCHP
Q1 26
$242.8M
Q4 25
$58.6M
$318.9M
Q3 25
$178.2M
$51.6M
Q2 25
$169.3M
$257.7M
Q1 25
$112.4M
$191.7M
Q4 24
$83.7M
$253.4M
Q3 24
$213.1M
$22.8M
Q2 24
$154.0M
$304.2M
FCF Margin
CRL
CRL
MCHP
MCHP
Q1 26
18.5%
Q4 25
5.9%
26.9%
Q3 25
17.7%
4.5%
Q2 25
16.4%
24.0%
Q1 25
11.4%
19.8%
Q4 24
8.4%
24.7%
Q3 24
21.1%
2.0%
Q2 24
15.0%
24.5%
Capex Intensity
CRL
CRL
MCHP
MCHP
Q1 26
5.6%
1.1%
Q4 25
8.9%
1.9%
Q3 25
3.5%
3.2%
Q2 25
3.4%
1.7%
Q1 25
6.0%
1.5%
Q4 24
7.5%
1.8%
Q3 24
3.8%
1.8%
Q2 24
3.8%
5.9%
Cash Conversion
CRL
CRL
MCHP
MCHP
Q1 26
Q4 25
5.44×
Q3 25
3.93×
2.11×
Q2 25
3.91×
Q1 25
6.74×
Q4 24
Q3 24
3.61×
0.56×
Q2 24
2.06×
2.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRL
CRL

Service revenue$798.2M80%
Product revenue$197.7M20%

MCHP
MCHP

Segment breakdown not available.

Related Comparisons